Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.14 per share, in line with the Zacks Consensus Estimate.
Cellebrite DI Ltd. (CLBT) Presents at UBS Global Technology and AI Conference 2025 Transcript
Cellebrite DI remains a long-term growth story, despite recent volatility and a modest stock decline since November 2024. CLBT's Q3 2025 earnings beat analyst expectations, with revenue up 18% year-over-year to $126 million and EPS of $0.14. Valuation and technical concerns persist, which could lead to further selling or an underperformance for the stock.
Cellebrite DI Ltd. ( CLBT ) Q3 2025 Earnings Call November 12, 2025 5:00 PM EST Company Participants Andrew Kramer - Vice President of Investor Relations Thomas Hogan - CEO & Director David Barter - Chief Financial Officer Marcus Jewell - Global Chief Revenue Officer Conference Call Participants Jeff Van Rhee - Craig-Hallum Capital Group LLC, Research Division Brian Essex - JPMorgan Chase & Co, Research Division Tomer Zilberman - BofA Securities, Research Division Louie Dipalma - William Blair & Company L.L.C.
Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.13 per share.
Cellebrite DI Ltd. (NASDAQ:CLBT ) Q2 2025 Earnings Call August 14, 2025 8:30 AM ET Company Participants Adam H.
Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.1 per share.
Cellebrite DI Ltd. (NASDAQ:CLBT ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Andrew Kramer - IR Tom Hogan - Interim CEO Dana Gerner - CFO Marcus Jewell - CRO Ronnen Armon - Chief Products and Technology Officer Conference Call Participants Tomer Zilberman - Bank of America Jeff Rhee - Craig-Hallum Mike Cikos - Needham Jonathan Ho - William Blair Shaul Eyal - TD Cowen Eric Martinuzzi - Lake Street Operator Welcome to the Cellebrite First Quarter 2025 Financial Results Conference Call.
Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.09 per share.
Cellebrite DI Ltd. (CLBT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
In this video, Anand Chokkavelu, Travis Hoium, and Lou Whiteman discuss Cellebrite (CLBT -5.53%), a key player in digital forensics for law enforcement. They provide ratings and insights on its growth potential, management, and financials, helping you decide if this stock is a worthy investment.
Cellebrite DI Ltd. (NASDAQ:CLBT ) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Andrew Kramer - IR Tom Hogan - Interim CEO Dana Gerner - CFO Marcus Jewell - CRO Ronnen Armon - Chief Products and Technology Officer Conference Call Participants Shaul Eyal - TD Cowen Bhavin Shah - Deutsche Bank Eric Martinuzzi - Lake Street Charlotte Bedick - JPMorgan Jeff Rhee - Craig-Hallum Mike Cikos - Needham Tomer Zilberman - Bank of America Louie DiPalma - William Blair Operator Welcome to the Cellebrite Fourth Quarter and Full Year 2024 Financial Results Conference Call.